In the phase 2 LiBBY trial presented, tetrahydrocannabinol and cannabidiol reduced agitation scores and improved clinician-rated outcomes in patients with advanced dementia.

Leiutis receives CDSCO approval for the world`s first synthetic cannabidiol oral solution for anxiety disorders in India.

Families caring for loved ones with advanced dementia and severe agitation now have a new piece of clinical evidence to weigh ...

High hopes for those with dementia. New research has found an unexpected benefit for a common symptom in those with ...

"Why would you repeat those damn lies? That destroys trust." -- Sen. Bill Cassidy, MD (R-La.), grilling President Trump's ...

Recent research published in the Journal of Psychopharmacology suggests that cannabidiol, a non-intoxicating compound found ...

Texas will ban delta-8, delta-10, THCP and other hemp products July 31. Here's what remains legal after the Supreme Court ...

A Phase II trial found that a THC-CBD oral formulation may reduce agitation in people with advanced dementia, but larger ...

Song Beam Bedding Co., Ltd., a premier sleep solutions provider in Taiwan, announced that a clinical sleep research project it sponsored—led by Chinese medicine and pharmacology expert Juan-Cheng Yang ...

Ananda Pharma Limited is a UK-based biopharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions. It has lead programmes in endometriosis and ...

Senator Ron Wyden (D-OR) is working with Democratic leadership to end the federal ban on marijuana.

In a first-of-its-kind clinical trial, U.S. researchers found that people with agitation and dementia in late life who took a ...